Skip to content
DataLookout
Menu

NCT03425643

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

The 49 most recent of 161 versions: 48 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
  2. Minor Study completion pushed from Jun 29, 2026 to Oct 15, 2026v161
  3. Minor Publications: details revised at 1 of 6 entriesv160
  4. Notable Results first posted: Sep 19, 2024
    • Secondary endpoints: details revised at 2 of 7 entries
    v159
  5. Minor Secondary endpoints: details revised at 2 of 7 entriesv158
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Secondary endpoints: 6 to 7v157
  2. Minor Enrollment target: estimated 786 to confirmed 797
    • Primary completion date changed from estimate of Jan 20, 2024 to Jul 10, 2023
    v156
  3. Minor Publications: details revised at 1 of 6 entriesv155
  4. Notable Eligibility criteria shortened, about 35 wordsv154
  5. Notable Eligibility criteria shortened, about 15 wordsv152
  6. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 227 of 227 sites
    v151
  7. Minor Site details revised at 3 of 227 sitesv150
  8. Minor Site details revised at 2 of 227 sitesv149
  9. Minor Site details revised at 4 of 227 sitesv148
  10. Minor Study sites revised (227)v147
  11. Minor Site details revised at 1 of 227 sitesv146
  12. Minor Site details revised at 4 of 227 sitesv145
  13. Minor Site details revised at 2 of 227 sitesv144
  14. Minor Study sites revised (227)v143
  15. Minor Site details revised at 8 of 227 sitesv142
  16. Minor Site details revised at 7 of 227 sitesv141
  17. Minor Study sites: 226 to 227v140
  18. Minor Site details revised at 1 of 226 sitesv139
  19. Minor Site details revised at 1 of 226 sitesv138
  20. Minor Study sites: 225 to 226v137
  21. Minor Site details revised at 3 of 225 sitesv136
  22. Minor Site details revised at 4 of 225 sitesv135
  23. Notable Eligibility criteria revised
    • Secondary endpoints: details revised at 6 of 6 entries
    • Site details revised at 7 of 225 sites
    v134
  24. Minor Site details revised at 1 of 225 sitesv133
  25. Minor Site details revised at 2 of 225 sitesv132
  26. Minor Study sites: 226 to 225v131
  27. Minor Site details revised at 4 of 226 sitesv130
  28. Minor Site details revised at 1 of 226 sitesv129
  29. Minor Site details revised at 2 of 226 sitesv128
  30. Minor Site details revised at 3 of 226 sitesv127
  31. Minor Site details revised at 1 of 226 sitesv126
  32. Minor Study sites: 225 to 226v125
  33. Minor Site details revised at 2 of 225 sitesv124
  34. Minor Site details revised at 3 of 225 sitesv123
  35. Minor Study sites: 224 to 225v122
  36. Minor Study sites: 222 to 224v121
  37. Minor Site details revised at 2 of 222 sitesv120
  38. Minor Study sites: 216 to 222v119
  39. Minor Study sites: 215 to 216v118
  40. Minor Study sites: 214 to 215v117
  41. Minor Site details revised at 1 of 214 sitesv116
  42. Minor Study sites: 213 to 214v115
  43. Minor Study sites: 212 to 213v114
  44. Minor Study sites: 211 to 212v113
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Event Free Survival (EFS)
Timeframe: Up to approximately 5 years
Overall Survival (OS)
Timeframe: Up to approximately 5 years

Secondary (7)

Major Pathological Response (mPR) Rate
Pathological Complete Response (pCR) Rate
Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score
Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score
Number of Participants Who Experience an Adverse Event (AE)
Show 2 moreShow less
Number of Participants Who Experience Perioperative Complications
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

Arms and interventions

NAC + Neoadjuvant/Adjuvant PembrolizumabExperimental

Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\]. Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, IV; given on cycle day 1\].

NAC + Neoadjuvant/Adjuvant PlaceboPlacebo comparator

Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\] in combination with platinum doublet NAC, consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\]. Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\].

Biologicals: Pembrolizumab

Drugs: Placebo, Cisplatin, Gemcitabine, Pemetrexed

Sites

227 sites in 25 countries

United States 51, China 15, Germany 15, Romania 13, Brazil 12, Japan 12, France 11, Argentina 10, Italy 10, Russia 9, Ukraine 9, Spain 8, United Kingdom 8, Belgium 6, Poland 6, Taiwan 6, Canada 5, South Korea 5, South Africa 4, Ireland 3, Australia 2, Latvia 2, Lithuania 2, Malaysia 2, Estonia 1